NFKB1 and hypertensive disorder: Bortezomib, a novel proteasome inhibitor, has been shown to possess anti-inflammatory effects by inhibiting the activation of NF-κB, effectively alleviating angiotensin II-induced hypertension and aortic remodeling [45, 46].